Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Satoh, Taroh | - |
dc.contributor.author | Lee, Kyung Hee | - |
dc.contributor.author | Rha, Sun Young | - |
dc.contributor.author | Sasaki, Yasutsuna | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Komatsu, Yoshito | - |
dc.contributor.author | Yasui, Hirofumi | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Yamaguchi, Kensei | - |
dc.contributor.author | Fuse, Nozomu | - |
dc.contributor.author | Yamada, Yasuhide | - |
dc.contributor.author | Ura, Takashi | - |
dc.contributor.author | Kim, Si-Young | - |
dc.contributor.author | Munakata, Masaki | - |
dc.contributor.author | Saitoh, Soh | - |
dc.contributor.author | Nishio, Kazuto | - |
dc.contributor.author | Morita, Satoshi | - |
dc.contributor.author | Yamamoto, Eriko | - |
dc.contributor.author | Zhang, Qingwei | - |
dc.contributor.author | Kim, Jung-mi | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.contributor.author | Sakata, Yuh | - |
dc.date.accessioned | 2021-09-04T11:55:38Z | - |
dc.date.available | 2021-09-04T11:55:38Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-10 | - |
dc.identifier.issn | 1436-3291 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/92286 | - |
dc.description.abstract | This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone (IRI) in patients with advanced gastric cancer (AGC) showing disease progression after previous 5-fluorouracil-based therapy. Irinotecan-naive patients (n = 82) received N-IRI (nimotuzumab 400 mg weekly plus irinotecan 150 mg/m(2) biweekly) or IRI (irinotecan 150 mg/m(2) biweekly) until disease progression. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), response rate (RR), safety, tolerability, and the correlation between efficacy and tumor epidermal growth factor receptor (EGFR) expression. Of 83 patients, 40 and 43 patients were randomly assigned to the N-IRI and IRI groups, respectively. In the N-IRI/IRI treatment group, median PFS was 73.0/85.0 days (P = 0.5668), and median OS and RR at 18 months were 250.5/232.0 days (P = 0.9778) and 18.4/10.3 %, respectively. Median PFS and OS in the EGFR 2+/3+ subgroups were 118.5/59.0 and 358.5/229.5 days, respectively. The RR was 33.3/0.0 % in the N-IRI/IRI treatment group. The incidence of grade 3 or higher adverse events was 77.5/64.3 %. No adverse events of grade 3 or higher skin rash or grade 3 or higher infusion-related reaction were reported. There was no superiority of N-IRI over IRI alone in terms of PFS in 5-fluorouracil-refractory AGC patients. However, N-IRI showed potential improvement in the EGFR 2+/3+ subgroup based on improved RR, PFS, and OS. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | GROWTH-FACTOR RECEPTOR | - |
dc.subject | ADVANCED ESOPHAGOGASTRIC CANCER | - |
dc.subject | MONOCLONAL-ANTIBODY H-R3 | - |
dc.subject | CELL LUNG-CANCER | - |
dc.subject | SUPPORTIVE CARE | - |
dc.subject | CHEMOTHERAPY PLUS | - |
dc.subject | 1ST-LINE THERAPY | - |
dc.subject | EGFR ANTIBODY | - |
dc.subject | CISPLATIN | - |
dc.subject | CAPECITABINE | - |
dc.title | Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yeul Hong | - |
dc.identifier.doi | 10.1007/s10120-014-0420-9 | - |
dc.identifier.scopusid | 2-s2.0-84942115572 | - |
dc.identifier.wosid | 000361488800016 | - |
dc.identifier.bibliographicCitation | GASTRIC CANCER, v.18, no.4, pp.824 - 832 | - |
dc.relation.isPartOf | GASTRIC CANCER | - |
dc.citation.title | GASTRIC CANCER | - |
dc.citation.volume | 18 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 824 | - |
dc.citation.endPage | 832 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | ADVANCED ESOPHAGOGASTRIC CANCER | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY H-R3 | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | CHEMOTHERAPY PLUS | - |
dc.subject.keywordPlus | 1ST-LINE THERAPY | - |
dc.subject.keywordPlus | EGFR ANTIBODY | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | CAPECITABINE | - |
dc.subject.keywordAuthor | Nimotuzumab | - |
dc.subject.keywordAuthor | Anti-EGFR | - |
dc.subject.keywordAuthor | Irinotecan | - |
dc.subject.keywordAuthor | Second-line therapy | - |
dc.subject.keywordAuthor | Advanced gastric cancer | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.